NTRK1 and neoplasm: Specifically, alkyne-modified sorafenib (targeting the receptor tyrosine kinase ligand) and the azido-modified VHL or cereblon ligand (E3 ubiquitin ligase recruiter) were synthesized for in situ assembly of tumor-specific PROTACs using CuAAC (Fig. 3).